<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39339947</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Epithelial Antimicrobial Peptide/Protein and Cytokine Expression Profiles Obtained from Nasopharyngeal Swabs of SARS-CoV-2-Infected and Non-Infected Subjects.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1471</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091471</ELocationID><Abstract><AbstractText>Immune responses of the epithelia of the upper respiratory tract are likely crucial in early inhibition of the viral replication and finally clearance of SARS-CoV-2. We aimed to compare the expression profiles of antimicrobial peptides/proteins (AMPs) and related cytokines observed in the nasopharynx of SARS-CoV-2-infected patients and non-infected controls and to assess the associations between these parameters and COVID-19 patients' outcomes. We included 45 subjects who had tested positive for SARS-CoV-2 and 22 control subjects who had tested negative for SARS-CoV-2. Biomaterial for SARS-CoV-2 detection, as well as gene and protein expression studies, was obtained from all subjects using nasopharyngeal swabs which were performed a maximum of 7 days before inclusion in the study. Univariable and multivariable statistics were performed. When compared to the controls, the mRNA expression levels of human β-defensin 1 (hBD-1), LL-37, and trappin-2 were significantly higher in specimens of nasopharyngeal swabs from COVID-19 patients. Protein expression of hBD-1 was also increased in the COVID-19 group. mRNA expression levels of interferon-ɣ (IFN-ɣ), tumor necrosis factor- ɑ (TNF-ɑ), and interleukin-6 (IL-6) measured in SARS-CoV-2-infected patients were significantly higher than those observed in the controls, which could also be confirmed in the protein levels of IFN-ɣ and IL-6. A significant correlation between mRNA and protein levels could be observed only for IL-6. Univariable analysis revealed that low IFN-ɣ mRNA levels were associated with severe/fatal outcomes. The occurrence of COVID-19 pneumonia was significantly associated with lower expression levels of IL-6 mRNA, IFN-ɣ mRNA, and TNF-ɑ mRNA. Concerning the severe/fatal outcomes, the multivariable logistic regression model revealed that none of the aforementioned parameters remained significant in the model. However, the logistic regression model revealed that higher TNF-ɑ mRNA expression was a significant independent predictor of absence of pneumonia [odds ratio: 0.35 (95% CI 0.14 to 0.88, <i>p</i> = 0.024)]. In conclusion, nasopharyngeal expression of AMPs (hBD-1, LL-37, and trappin-2) and cytokines (IL-6, IFN-ɣ, and TNF-ɑ) is upregulated in response to early SARS-CoV-2 infection, indicating that these AMPs and cytokines play a role in the local host defense against the virus. Upregulated nasopharyngeal TNF-ɑ mRNA expression during the early phase of SARS-CoV-2 infection was a significant independent predictor of the absence of COVID-19 pneumonia. Hence, high TNF-ɑ mRNA expression in the nasopharynx appears to be a protective factor for lung complications in COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gambichler</LastName><ForeName>Thilo</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7862-3695</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Ruhr-University Bochum, 44791 Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Dortmund Hospital, Faculty of Health, School of Medicine, University Witten/Herdecke, 44137 Dortmund, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Christian Hospital Unna, 59423 Unna, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goesmann</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Ruhr-University Bochum, 44791 Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skrygan</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Ruhr-University Bochum, 44791 Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Susok</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Ruhr-University Bochum, 44791 Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Dortmund Hospital, Faculty of Health, School of Medicine, University Witten/Herdecke, 44137 Dortmund, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schütte</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ruhr-University Bochum, 44791 Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamdani</LastName><ForeName>Nahza</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3053-0008</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Experimental Cardiology, Ruhr-University Bochum, 44791 Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Ruhr-University Bochum, 44791 Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Physiology, Ruhr-University Bochum, 44801 Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ruhr-University Bochum, 44791 Bochum, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000089882">Antimicrobial Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="Y">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089882" MajorTopicYN="Y">Antimicrobial Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">RNase-7</Keyword><Keyword MajorTopicYN="N">S100A7</Keyword><Keyword MajorTopicYN="N">SALP/elafin</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antimicrobial peptides</Keyword><Keyword MajorTopicYN="N">antimicrobial proteins</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">pro-inflammatory cytokines</Keyword><Keyword MajorTopicYN="N">psoriasin</Keyword></KeywordList><CoiStatement>The other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339947</ArticleId><ArticleId IdType="pmc">PMC11437508</ArticleId><ArticleId IdType="doi">10.3390/v16091471</ArticleId><ArticleId IdType="pii">v16091471</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asaba C.N., Ekabe C.J., Ayuk H.S., Gwanyama B.N., Bitazar R., Bukong T.N. Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections. J. Inflamm. Res. 2024;17:5077–5091. doi: 10.2147/JIR.S474707.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S474707</ArticleId><ArticleId IdType="pmc">PMC11288317</ArticleId><ArticleId IdType="pubmed">39081874</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambichler T., Schuleit N., Susok L., Becker J.C., Scheel C.H., Torres-Reyes C., Overheu O., Reinacher-Schick A., Schmidt W. Prognostic Performance of Inflammatory Biomarkers Based on Complete Blood Counts in COVID-19 Patients. Viruses. 2023;15:1920. doi: 10.3390/v15091920.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15091920</ArticleId><ArticleId IdType="pmc">PMC10536301</ArticleId><ArticleId IdType="pubmed">37766326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Peng Y., Wu X., Pang B., Yang F., Zheng W., Liu C., Zhang J. Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis. Front. Public Health. 2022;10:923485. doi: 10.3389/fpubh.2022.923485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.923485</ArticleId><ArticleId IdType="pmc">PMC9424916</ArticleId><ArticleId IdType="pubmed">36052001</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Shajlawi M., Alsayed A.R., Abazid H., Awajan D., Al-Imam A., Basheti I. Using laboratory parameters as predictors for the severity and mortality of COVID-19 in hospitalized patients. Pharm. Pract. 2022;20:2721. doi: 10.18549/PharmPract.2022.3.2721.</Citation><ArticleIdList><ArticleId IdType="doi">10.18549/PharmPract.2022.3.2721</ArticleId><ArticleId IdType="pmc">PMC9851820</ArticleId><ArticleId IdType="pubmed">36733508</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedi T., Raj A., Das N., Gupta R., Gupta N., Tiwari P., Sahoo B., Sagiraju H.K.R., Sirohiya P., Ratre B., et al. The Evaluation of Laboratory Parameters as Predictors of Disease Severity and Mortality in COVID-19 Patients: A Retrospective Study from a Tertiary Care Hospital in India. Cureus. 2023;15:e40273. doi: 10.7759/cureus.40273.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.40273</ArticleId><ArticleId IdType="pmc">PMC10336329</ArticleId><ArticleId IdType="pubmed">37448393</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzaniga M., Fumagalli L.A.M., D’angelo L., Cerino M., Bonfanti G., Fumagalli R.M., Schiavo G., Lorini C., Lainu E., Terragni S., et al. Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia. Int. J. Clin. Pract. 2021;75:e14047. doi: 10.1111/ijcp.14047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14047</ArticleId><ArticleId IdType="pmc">PMC7995195</ArticleId><ArticleId IdType="pubmed">33497517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fröberg J., Diavatopoulos D.A. Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection. Curr. Opin. Infect. Dis. 2021;34:181–186. doi: 10.1097/QCO.0000000000000724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000724</ArticleId><ArticleId IdType="pubmed">33899752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty M.C., Varose S.Y., Sawant U.P., Fernandes M.M. Expression of innate immune response genes in upper airway samples of SARS-CoV-2 infected patients: A preliminary study. Indian J. Med. Res. 2021;153:677–683. doi: 10.4103/ijmr.IJMR_131_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmr.IJMR_131_21</ArticleId><ArticleId IdType="pmc">PMC8555587</ArticleId><ArticleId IdType="pubmed">34528526</ArticleId></ArticleIdList></Reference><Reference><Citation>Baindara P., Ganguli S., Chakraborty R., Mandal S.M. Preventing Respiratory Viral Diseases with Antimicrobial Peptide Master Regulators in the Lung Airway Habitat. Clin. Pract. 2023;13:125–147. doi: 10.3390/clinpract13010012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/clinpract13010012</ArticleId><ArticleId IdType="pmc">PMC9844411</ArticleId><ArticleId IdType="pubmed">36648852</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura M., Kamiya K., Furuhata A., Ikeda K., Niyonsaba F. S100A7 Co-localization and Up-regulation of Filaggrin in Human Sinonasal Epithelial Cells. Curr. Med. Sci. 2021;41:863–868. doi: 10.1007/s11596-021-2431-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11596-021-2431-1</ArticleId><ArticleId IdType="pubmed">34643881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandi J.D., Levy J.I., Tapela K., Zeller M., Yeboah J.A., Saka D.F., Grant D.S., Awandare G.A., Quashie P.K., Andersen K.G., et al. Upper Airway Epithelial Tissue Transcriptome Analysis Reveals Immune Signatures Associated with COVID-19 Severity in Ghanaians. J. Immunol. Res. 2024;2024:6668017. doi: 10.1155/2024/6668017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2024/6668017</ArticleId><ArticleId IdType="pmc">PMC10876312</ArticleId><ArticleId IdType="pubmed">38375062</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudien M., Dressel S., Harder J., Gläser R. Differential expression pattern of antimicrobial peptides in nasal mucosa and secretion. Rhinology. 2011;49:107–111. doi: 10.4193/Rhino10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.4193/Rhino10.036</ArticleId><ArticleId IdType="pubmed">21468384</ArticleId></ArticleIdList></Reference><Reference><Citation>Amatngalim G.D., van Wijck Y., de Mooij-Eijk Y., Verhoosel R.M., Harder J., Lekkerkerker A.N., Janssen R.A., Hiemstra P.S. Basal cells contribute to innate immunity of the airway epithelium through production of the antimicrobial protein RNase 7. J. Immunol. 2015;194:3340–3350. doi: 10.4049/jimmunol.1402169.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1402169</ArticleId><ArticleId IdType="pubmed">25712218</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeret B., Solhonne B., Straube M., Lemaire F., Cazes A., Garcia-Verdugo I., Sallenave J.M. Influenza A Virus Pre-Infection Exacerbates Pseudomonas aeruginosa-Mediated Lung Damage Through Increased MMP-9 Expression, Decreased Elafin Production and Tissue Resilience. Front. Immunol. 2020;11:117. doi: 10.3389/fimmu.2020.00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00117</ArticleId><ArticleId IdType="pmc">PMC7031978</ArticleId><ArticleId IdType="pubmed">32117268</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanga A., Saidi A., Jourdan M.L., Dallet-Choisy S., Zani M.L., Moreau T. Protection of lung epithelial cells from protease-mediated injury by trappin-2 A62L, an engineered inhibitor of neutrophil serine proteases. Biochem. Pharmacol. 2012;83:1663–1673. doi: 10.1016/j.bcp.2012.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2012.03.009</ArticleId><ArticleId IdType="pubmed">22465040</ArticleId></ArticleIdList></Reference><Reference><Citation>Roubidoux E.K., Brigleb P.H., Vegesana K., Souquette A., Whitt K., Freiden P., St. Jude Investigative Team. Green A., Thomas P.G., McGargill M.A., et al. Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2. Sci. Rep. 2023;13:17820. doi: 10.1038/s41598-023-44989-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-44989-5</ArticleId><ArticleId IdType="pmc">PMC10587113</ArticleId><ArticleId IdType="pubmed">37857783</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D., Ejghal R., Desterke C., Outlioua A., Hammi I., Lemrani M., Hilali F., Guessous F., Zaid Y., Akarid K. Type I and III interferons are good markers to monitor COVID-19 pathophysiology. Cytokine. 2023;165:156172. doi: 10.1016/j.cyto.2023.156172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2023.156172</ArticleId><ArticleId IdType="pmc">PMC10008794</ArticleId><ArticleId IdType="pubmed">36924609</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobova Z.R., Arsentieva N.A., Liubimova N.E., Batsunov O.K., Dedkov V.G., Gladkikh A.S., Sharova A.A., Adish Z., Chernykh E.I., Kaschenko V.A., et al. Cytokine Profiling in Different SARS-CoV-2 Genetic Variants. Int. J. Mol. Sci. 2022;23:14146. doi: 10.3390/ijms232214146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232214146</ArticleId><ArticleId IdType="pmc">PMC9692520</ArticleId><ArticleId IdType="pubmed">36430621</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain R., Ramaswamy S., Harilal D., Uddin M., Loney T., Nowotny N., Alsuwaidi H., Varghese R., Deesi Z., Alkhajeh A., et al. Host transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomes. Comput. Struct. Biotechnol. J. 2020;19:153–160. doi: 10.1016/j.csbj.2020.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2020.12.016</ArticleId><ArticleId IdType="pmc">PMC7773686</ArticleId><ArticleId IdType="pubmed">33425248</ArticleId></ArticleIdList></Reference><Reference><Citation>Akgun E., Tuzuner M.B., Sahin B., Kilercik M., Kulah C., Cakiroglu H.N., Serteser M., Unsal I., Baykal A.T. Proteins associated with neutrophil degranulation are upregulated in nasopharyngeal swabs from SARS-CoV-2 patients. PLoS ONE. 2020;15:e0240012. doi: 10.1371/journal.pone.0240012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240012</ArticleId><ArticleId IdType="pmc">PMC7575075</ArticleId><ArticleId IdType="pubmed">33079950</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert C., Lefeuvre C., Preisser L., Pivert A., Soleti R., Blanchard S., Delneste Y., Ducancelle A., Couez D., Jeannin P. Age-Related Expression of IFN-λ1 Versus IFN-I and Beta-Defensins in the Nasopharynx of SARS-CoV-2-Infected Individuals. Front. Immunol. 2021;12:750279. doi: 10.3389/fimmu.2021.750279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.750279</ArticleId><ArticleId IdType="pmc">PMC8631500</ArticleId><ArticleId IdType="pubmed">34858406</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello A., Grossi A., Meschi S., Meledandri M., Vanini V., Petrone L., Casetti R., Cuzzi G., Salmi A., Altera A.M., et al. Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. Front. Immunol. 2022;13:920227. doi: 10.3389/fimmu.2022.920227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.920227</ArticleId><ArticleId IdType="pmc">PMC9364317</ArticleId><ArticleId IdType="pubmed">35967321</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X., Song J.W., Cao W.J., Zhou M.J., Yang T., Wang J., Meng F.P., Shi M., Zhang C., Wang F.S. T-Cell Epitope Mapping of SARS-CoV-2 Reveals Coordinated IFN-γ Production and Clonal Expansion of T Cells Facilitates Recovery from COVID-19. Viruses. 2024;16:1006. doi: 10.3390/v16071006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16071006</ArticleId><ArticleId IdType="pmc">PMC11281491</ArticleId><ArticleId IdType="pubmed">39066169</ArticleId></ArticleIdList></Reference><Reference><Citation>de Azambuja Pias Weber A., Viero F.T., Pillat M.M., de Lima Gonçalves T. Changes in markers of inflammation and their correlation with death in patients with COVID-19 in the intensive care unit. Cytokine. 2024;175:156509. doi: 10.1016/j.cyto.2024.156509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2024.156509</ArticleId><ArticleId IdType="pubmed">38241964</ArticleId></ArticleIdList></Reference><Reference><Citation>Viermyr H.K., Halvorsen B., Sagen E.L., Michelsen A.E., Barrat-Due A., Kåsine T., Nezvalova-Henriksen K., Dyrhol-Riise A.M., Nor-Solidarity Consortium. Lerum T.V., et al. High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial. J. Intern. Med. 2024 doi: 10.1111/joim.13820. epub ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13820</ArticleId><ArticleId IdType="pubmed">39011800</ArticleId></ArticleIdList></Reference><Reference><Citation>Pita-Martínez C., Pérez-García F., Virseda Berdices A., Martin-Vicente M., Castilla-García L., Hervás Fernández I., González Ventosa V., Muñoz-Gómez M.J., Cuadros-González J., Bermejo-Martin J.F., et al. A deficient immune response to SARS-CoV-2 in the nasopharynx is associated with severe COVID-19 pneumonia. Int. J. Infect. Dis. 2023;134:126–132. doi: 10.1016/j.ijid.2023.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.06.001</ArticleId><ArticleId IdType="pmc">PMC10245280</ArticleId><ArticleId IdType="pubmed">37290572</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-García F., Martin-Vicente M., Rojas-García R.L., Castilla-García L., Muñoz-Gomez M.J., Hervás Fernández I., González Ventosa V., Vidal-Alcántara E.J., Cuadros-González J., Bermejo-Martin J.F., et al. High SARS-CoV-2 Viral Load and Low CCL5 Expression Levels in the Upper Respiratory Tract Are Associated With COVID-19 Severity. J. Infect. Dis. 2022;225:977–982. doi: 10.1093/infdis/jiab604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab604</ArticleId><ArticleId IdType="pmc">PMC8754799</ArticleId><ArticleId IdType="pubmed">34910814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu J.K., Siggins M.K., Liew F., Russell C.D., Uruchurtu A.S.S., Davis C., Turtle L., Moore S.C., Hardwick H.E., Oosthuyzen W., et al. Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19. J. Infect. Dis. 2024;230:e17–e29. doi: 10.1093/infdis/jiad590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad590</ArticleId><ArticleId IdType="pmc">PMC11272059</ArticleId><ArticleId IdType="pubmed">39052740</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith N., Goncalves P., Charbit B., Grzelak L., Beretta M., Planchais C., Bruel T., Rouilly V., Bondet V., Hadjadj J., et al. Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. Nat. Immunol. 2021;22:1428–1439. doi: 10.1038/s41590-021-01028-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01028-7</ArticleId><ArticleId IdType="pmc">PMC8553615</ArticleId><ArticleId IdType="pubmed">34471264</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker T. The early interferon catches the SARS-CoV-2. J. Exp. Med. 2021;218:e20211667. doi: 10.1084/jem.20211667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211667</ArticleId><ArticleId IdType="pmc">PMC8404473</ArticleId><ArticleId IdType="pubmed">34424267</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi A., Cazzolla A.P., Lovero R., Lo Muzio L., Testa N.F., Ciavarella D., Palmieri G., Pozzessere P., Procacci V., Di Serio F., et al. New Insights in Laboratory Testing for COVID-19 Patients: Looking for the Role and Predictive Value of Human epididymis secretory protein 4 (HE4) and the Innate Immunity of the Oral Cavity and Respiratory Tract. Microorganisms. 2020;8:1718. doi: 10.3390/microorganisms8111718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8111718</ArticleId><ArticleId IdType="pmc">PMC7692217</ArticleId><ArticleId IdType="pubmed">33147871</ArticleId></ArticleIdList></Reference><Reference><Citation>Nireeksha N., Gollapalli P., Varma S.R., Hegde M.N., Kumari N.S. Utilizing the Potential of Antimicrobial Peptide LL-37 for Combating SARS-COV- 2 Viral Load in Saliva: An In Silico Analysis. Eur. J. Dent. 2022;16:478–487. doi: 10.1055/s-0041-1739444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1739444</ArticleId><ArticleId IdType="pmc">PMC9507610</ArticleId><ArticleId IdType="pubmed">34937110</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosta E. The seven constitutive respiratory defense barriers against SARS-CoV-2 infection. Rev. Soc. Bras. Med. Trop. 2021;54:e04612021. doi: 10.1590/0037-8682-0461-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0037-8682-0461-2021</ArticleId><ArticleId IdType="pmc">PMC8687496</ArticleId><ArticleId IdType="pubmed">34932765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bals R. Epithelial antimicrobial peptides in host defense against infection. Respir. Res. 2000;1:141–150. doi: 10.1186/rr25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/rr25</ArticleId><ArticleId IdType="pmc">PMC59560</ArticleId><ArticleId IdType="pubmed">11667978</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Wang A., Marin M., Honnen W., Ramasamy S., Porter E., Subbian S., Pinter A., Melikyan G.B., Lu W., et al. Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry. Viruses. 2021;13:1246. doi: 10.3390/v13071246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13071246</ArticleId><ArticleId IdType="pmc">PMC8310277</ArticleId><ArticleId IdType="pubmed">34206990</ArticleId></ArticleIdList></Reference><Reference><Citation>Keutmann M., Hermes G., Meinberger D., Roth A., Stemler J., Cornely O.A., Klatt A.R., Streichert T. The ratio of serum LL-37 levels to blood leucocyte count correlates with COVID-19 severity. Sci. Rep. 2022;12:9447. doi: 10.1038/s41598-022-13260-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13260-8</ArticleId><ArticleId IdType="pmc">PMC9175165</ArticleId><ArticleId IdType="pubmed">35676519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardelli M., Pierpaoli E., Marchegiani F., Marcheselli F., Piacenza F., Giacconi R., Recchioni R., Casoli T., Stripoli P., Provinciali M., et al. Biomarkers of cell damage, neutrophil and macrophage activation associated with in-hospital mortality in geriatric COVID-19 patients. Immun. Ageing. 2022;19:65. doi: 10.1186/s12979-022-00315-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-022-00315-7</ArticleId><ArticleId IdType="pmc">PMC9751505</ArticleId><ArticleId IdType="pubmed">36522763</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Chen P., Shi T., Mehmood A., Qiu J. HD5 and LL-37 Inhibit SARS-CoV and SARS-CoV-2 Binding to Human ACE2 by Molecular Simulation. Interdiscip. Sci. 2021;13:766–777. doi: 10.1007/s12539-021-00462-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12539-021-00462-3</ArticleId><ArticleId IdType="pmc">PMC8346780</ArticleId><ArticleId IdType="pubmed">34363600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci V., Miceli M., Pagliuca C., Bianco O., Castaldo L., Izzo L., Cozzolino M., Zannella C., Oglio F., Polcaro A., et al. Modulation of innate immunity related genes resulting in prophylactic antimicrobial and antiviral properties. J. Transl. Med. 2024;22:574. doi: 10.1186/s12967-024-05378-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-024-05378-2</ArticleId><ArticleId IdType="pmc">PMC11184722</ArticleId><ArticleId IdType="pubmed">38886736</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittayananta W., Lerdsamran H., Chutiwitoonchai N., Promsong A., Srichana T., Netsomboon K., Prasertsopon J., Kerdto J. A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity. Virol. J. 2024;21:26. doi: 10.1186/s12985-023-02282-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-02282-x</ArticleId><ArticleId IdType="pmc">PMC10807123</ArticleId><ArticleId IdType="pubmed">38263162</ArticleId></ArticleIdList></Reference><Reference><Citation>Idris M.M., Banu S., Siva A.B., Nagaraj R. Down regulation of defensin genes during SARS-CoV-2 infection. Acta Virol. 2022;66:249–253. doi: 10.4149/av_2022_306.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/av_2022_306</ArticleId><ArticleId IdType="pubmed">36029089</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 2020;20:e192–e197. doi: 10.1016/S1473-3099(20)30483-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Bayatee N.T., Ad’hiah A.H. Human beta-defensins 2 and 4 are dysregulated in patients with coronavirus disease 19. Microb. Pathog. 2021;160:105205. doi: 10.1016/j.micpath.2021.105205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.105205</ArticleId><ArticleId IdType="pmc">PMC8450228</ArticleId><ArticleId IdType="pubmed">34547411</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancaccio M., Mennitti C., Calvanese M., Gentile A., Musto R., Gaudiello G., Scamardella G., Terracciano D., Frisso G., Pero R., et al. Diagnostic and Therapeutic Potential for HNP-1, HBD-1 and HBD-4 in Pregnant Women with COVID-19. Int. J. Mol. Sci. 2022;23:3450. doi: 10.3390/ijms23073450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23073450</ArticleId><ArticleId IdType="pmc">PMC8998699</ArticleId><ArticleId IdType="pubmed">35408809</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloul K.M., Nielsen J.E., Defensor E.B., Lin J.S., Fortkort J.A., Shamloo M., Cirillo J.D., Gombart A.F., Barron A.E. Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis. Front. Immunol. 2022;13:880961. doi: 10.3389/fimmu.2022.880961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.880961</ArticleId><ArticleId IdType="pmc">PMC9134243</ArticleId><ArticleId IdType="pubmed">35634307</ArticleId></ArticleIdList></Reference><Reference><Citation>de Buhr N., Parplys A.C., Schroeder M., Henneck T., Schaumburg B., Stanelle-Bertram S., Jarczak D., Nierhaus A., Hiller J., Peine S., et al. Impaired Degradation of Neutrophil Extracellular Traps: A Possible Severity Factor of Elderly Male COVID-19 Patients. J. Innate Immun. 2022;14:461–476. doi: 10.1159/000521594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000521594</ArticleId><ArticleId IdType="pmc">PMC9059026</ArticleId><ArticleId IdType="pubmed">35086104</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhut M., Shin J.I. Pathways in the Pathophysiology of Coronavirus 19 Lung Disease Accessible to Prevention and Treatment. Front. Physiol. 2020;11:872. doi: 10.3389/fphys.2020.00872.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.00872</ArticleId><ArticleId IdType="pmc">PMC7457053</ArticleId><ArticleId IdType="pubmed">32922301</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth A., Lutke S., Meinberger D., Hermes G., Sengle G., Koch M., Streichert T., Klatt A.R. LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro. bioRxiv. 2020 doi: 10.1101/2020.12.02.408153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.02.408153</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheemarla N.R., Watkins T.A., Mihaylova V.T., Wang B., Zhao D., Wang G., Landry M.L., Foxman E.F. Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. J. Exp. Med. 2021;218:e20210583. doi: 10.1084/jem.20210583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210583</ArticleId><ArticleId IdType="pmc">PMC8210587</ArticleId><ArticleId IdType="pubmed">34128960</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu K.H., Yip C.C., Poon R.W., Leung K.H., Li X., Hung I.F., To K.K., Cheng V.C., Yuen K.Y. Correlations of Myeloperoxidase (MPO), Adenosine deaminase (ADA), C-C motif chemokine 22 (CCL22), Tumour necrosis factor alpha (TNFα) and Interleukin-6 (IL-6) mRNA expression in the nasopharyngeal specimens with the diagnosis and severity of SARS-CoV-2 infections. Emerg. Microbes Infect. 2023;12:2157338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9809351</ArticleId><ArticleId IdType="pubmed">36482706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghulam U., Nazim F., Farooqui N., Rizwan-Ul-Hasan S., Anwar M.F., Ahmed K., Jamal A., Kayani H.A., Mughal N., Hussain A., et al. Analysis of differential gene expression of pro-inflammatory cytokines in the nasopharyngeal milieu of mild &amp; severe COVID-19 cases. PLoS ONE. 2022;17:e0279270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9803207</ArticleId><ArticleId IdType="pubmed">36584119</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambichler T., Reuther J., Scheel C.H., Becker J.C. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. J. Immunother. Cancer. 2020;8:e001145. doi: 10.1136/jitc-2020-001145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001145</ArticleId><ArticleId IdType="pmc">PMC7358098</ArticleId><ArticleId IdType="pubmed">32611687</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfieri L., Franceschetti L., Frisoni P., Bonato O., Radaelli D., Bonuccelli D., D’Errico S., Neri M. Cardiac SARS-CoV-2 Infection, Involvement of Cytokines in Postmortem Immunohistochemical Study. Diagnostics. 2024;14:787. doi: 10.3390/diagnostics14080787.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics14080787</ArticleId><ArticleId IdType="pmc">PMC11049034</ArticleId><ArticleId IdType="pubmed">38667433</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>